Pharmala’s Investigator’s Brochure for MDMA researchers describes the physical, chemical, and pharmacological characteristics of MDMA, its effects in nonclinical and clinical studies, and the safety profile of MDMA-assisted therapy. This brochure focuses on research and information relevant to researchers and regulators engaged in clinical trials with MDMA. To contact Pharmala about obtaining GMP MDMA for government-regulated research, contact Conway Gaskin, conway@pharmala.ca
Optimi Labs’ Investigator’s Brochure for OPTI-MHCL (MDMA HCl) describes the physical, chemical, and pharmacological characteristics of MDMA, its effects in nonclinical and clinical studies, and the safety profile relevant to MDMA-assisted research. The brochure is intended for researchers and regulators conducting clinical trials with MDMA. To contact Optimi Labs about obtaining GMP MDMA for government-regulated research, reach out at info@optimihealth.ca or 778-761-4551.
This report covers clinical, nonclinical, and manufacturing research updates from the MDMA Clinical Development Program sponsored by MAPS or MAPS Europe B.V. through October 1 of each year. This report was prepared and submitted by the MAPS Public Benefit Corporation (MAPS PBC).
Additional Resources
- Treatment Manual: MDMA-Assisted Therapy for PTSD
- A Manual for Adherence Ratings of MDMA-Assisted Therapy for Treatment of Posttraumatic Stress Disorder
- MDMA Scientific Literature, Government Hearings, and Archive
- MDMA Literature Review
- Participant Safety in Psychedelic Therapy
- More MDMA Resources from MAPS
- MDMA Resources from Other Sites
- Accounts of MDMA’s Healing Effects

